5-(4-(trimethylstannyl)phenyl)-1H-imidazole | 1021919-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-(trimethylstannyl)phenyl)-1H-imidazole
• 英文别名: [4-(1H-imidazol-5-yl)phenyl]-trimethylstannane
• CAS: 1021919-41-4
• 化学式: C₁₂H₁₆N₂Sn
• 分子量: 306.982
• InChiKey: DXZJTYASJDTHOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.62
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(4-(trimethylstannyl)phenyl)-1H-imidazole 、 6-bromo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 在 trans-bis(triphenylphosphine)palladium dichloride 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 乙醚 、 水 为溶剂， 反应 1.5h， 以37%的产率得到6-(4-(1H-imidazol-5-yl)phenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one hydrochloride
  参考文献：
  名称：

  Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors

  摘要：

  We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[ 4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3K alpha lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.035
• 作为产物：
  描述：

  六甲基二锡 、 4-(4-溴苯基)-1H-咪唑 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以36%的产率得到5-(4-(trimethylstannyl)phenyl)-1H-imidazole
  参考文献：
  名称：

  WO2008/51493

  摘要：

  公开号：

文献信息

• WO2008/51493
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors
  作者：Deborah S. Mortensen、Sophie M. Perrin-Ninkovic、Roy Harris、Branden G.S. Lee、Graziella Shevlin、Matt Hickman、Gody Khambatta、Rene R. Bisonette、Kimberly E. Fultz、Sabita Sankar

  DOI：10.1016/j.bmcl.2011.09.035

  日期：2011.11

  We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[ 4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3K alpha lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473). (C) 2011 Elsevier Ltd. All rights reserved.